Pfizer Settles in Celebrex Investor Lawsuit
Pfizer Inc. has decided to pay $164 million to settle a shareholder class action consumer fraud lawsuit that alleged that the company misled investors about clinical trial results for its arthritis drug Celebrex. Reuters reports that the world’s largest pharmaceutical company denies any wrongdoing in the matter. The settlement was unveiled — just two weeks